| SBHMY Stock | | | USD 9.05 0.00 0.00% |
CEO
Mr. Tse Ping serves as Chief Executive Officer, Executive Director of the Company. He is responsible for the overall operations of the Group. With more than 25 years of extensive experience in investment and management in the pharmaceutical industry in China, he is currently a director of CT Tianqing, NJCTT, Jiangsu CT Fenghai, Jiangsu CT Qingjiang, Qingdao CT, and Beijing Tide. He is also a director of Shanghai Fortune World Development Co., Ltd., Tianjin Chiatai Feed Tech Co., Ltd., SYN Energy Technology Co., Ltd. and Chia Tai Oversea Chinese Realty Development Co., Ltd., and a non executive director of Tianjin Binhai Teda Logistics Corporation Limited, the shares of which are listed on GEM Board of the Stock Exchange since 2016.
| Age | 71 |
| Tenure | 8 years |
| Phone | 852 2802 9886 |
| Web | https://www.sinobiopharm.com |
Tse still acts as a director of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. and a council member of the Association of Pharmaceutical Biotechnology of China.
Sino Biopharmaceutica Management Efficiency
The company has return on total asset
(ROA) of
0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.
Sino Biopharmaceutical Ltd has accumulated 5.21
B in total debt with debt to equity ratio
(D/E) of 0.31, which is about average as compared to similar companies. Sino Biopharmaceutical has a current ratio of 1.52, which is within standard range for the sector. Debt can assist Sino Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Sino Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sino Biopharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sino to invest in growth at high rates of return. When we think about Sino Biopharmaceutica's use of debt, we should always consider it together with cash and equity.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutica is traded on OTC Exchange in the United States. Sino Biopharmaceutical Ltd [SBHMY] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Sino Biopharmaceutical Leadership Team
Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cheung Cheng, Executive Vice Chairlady of the Board | |
| Fai Chia, Assistant to the President and Vice President | |
| Wei Ye, Assistant President General Manager - R&D Department | |
| Ping Tse, CEO, Executive Director | |
| Mingqin Li, Vice President Executive Director | |
| Wun Tse, Assistant to the President | |
| Zhoushan Tian, Executive Director | |
| Y Tse, Executive Chairlady of the Board | |
| Hsin Tse, Vice President Executive Director | |
| Eric Tse, CEO Director | |
Sino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Sino Pink Sheet Analysis
When running Sino Biopharmaceutica's price analysis, check to
measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to
predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.